**REMIND Phenotype cohort**

| Variable                                      | Value          |
|-----------------------------------------------|----------------|
| Gender                                        | Male 34 (47%), Female 38 (53%) |
| Median Age, yr (IQR)                         | 32.6 (26.8-45.0) |
| Age at CD Diagnosis                          |                |
| - <16 years (A1)                              | 11 (15%)       |
| - 17-40 years (A2)                            | 53 (74%)       |
| - >40 years (A3)                              | 8 (11%)        |
| Median disease duration, yr (IQR)             | 10.4 (3.85-19.4) |
| Smoking                                       |                |
| - Non smokers                                 | 27 (38%)       |
| - Active smokers at surgery                   | 31 (43%)       |
| - Ex smokers                                  | 14 (19%)       |
| Previous intestinal resection                 |                |
| - Yes                                         | 22 (31%)       |
| - No                                          | 50 (69%)       |
| Number of previous resection(s)               |                |
| - 0                                           | 50 (69%)       |
| - 1                                           | 14 (19%)       |
| - 2                                           | 5 (7%)         |
| - 3                                           | 3 (5%)         |
| Surgical indication                           |                |
| - Stricturing complication                    | 38 (53%)       |
| - Penetrating complication                    | 33 (46%)       |
| - Failure of drug therapy                     | 1 (1%)         |
| Disease location (Montreal classification)    |                |
| - Ileal (L1)                                  | 43 (60%)       |
| - Ileocolonic (L3)                            | 29 (40%)       |
| - Anoperineal lesions                         | 13 (18%)       |
| Extradigestive symptoms                      |                |
| - Joint manifestations                        | 8 (11%)        |
| - Skin manifestations                         | 3 (4%)         |
| - Eye manifestations                          | 0              |
| Previous exposure to anti-TNF therapy         | 44 (61%)       |
| Previous exposure to thiopurines              | 51 (71%)       |
| Inflamed margin of resection                  | 9 (13%)        |